Sorry, I don't understand. Please try again

Oncology latest news

Oncology

Early results from Johnson & Johnson’s trispecific antibody show promising response in heavily pretreated multiple myeloma patients

June 3, 2025
Oncology

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity

June 3, 2025
Oncology

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

June 3, 2025
Oncology

Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-mutated mCSPC

June 3, 2025
Oncology

Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer

June 1, 2025
Oncology

Johnson & Johnson showcases latest advancements in cancer innovation with more than 70 clinical and real-world studies at ASCO and EHA

May 22, 2025
Oncology

U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

May 21, 2025
Oncology

Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC

April 26, 2025
Oncology

Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer

April 26, 2025
Oncology

Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA

April 21, 2025